MS Views and News Be empowered with MS views and news. To receive The MS BEACON e-Newsletter, CLICK HERE - -

Visit our MS learning channel on YouTube, which provides hundreds of MS educational videos presented by MS Experts from across the USA. Archived here: www.youtube.com/msviewsandnews -- Also please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for the MS community. Furthermore, scroll down the left side of this blog to learn from the resources and links.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~


Thursday, April 21, 2011

Acorda Therapeutics announces US patent for multiple sclerosis drug "Ampyra"


With no competition, shall there be higher prices?




April 21, 2011


(Source: Datamonitor)tracking
Acorda Therapeutics, Inc., a biotechnology company, has announced that the US Patent and Trademark Office has allowed US patent application entitled Sustained Release Aminopyridine Composition.


The claims of the patent application relate to methods to improve walking in patients with multiple sclerosis (MS) by administering 10 mg of sustained release 4-aminopyridine (dalfampridine) twice daily. The patent that issues from this application, which will be eligible for listing in the FDA Orange Book, is set to expire in early February 2026, based on the USPTO's calculated patent term adjustment of 413 days, which the Company is currently evaluating.

AMPYRA (dalfampridine) Extended Release Tablets, 10 mg is marketed in the US by Acorda Therapeutics, Inc. It is approved in the Unites States as a treatment to improve walking in people with MS. This was demonstrated by an increase in walking speed.
A service of YellowBrix, Inc





****************************************************************
Remain CURRENT with Multiple Sclerosis information 
 when registered at the  MS Views and News  website
.
***************************************************************************************
Help to Educate:  Please donate   - all contributions are tax deductible - 
.
"Providing You with 'MS Views and News'is what we do"
***************************************************************************************
.
Disclaimer:  'MS Views and News' (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
.
 ****************************************************************

No comments: